192 related articles for article (PubMed ID: 31950015)
1. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
Watanabe K; Sugiyama T; Otsuka A; Miyake H
Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
[TBL] [Abstract][Full Text] [Related]
2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.
Danno T; Iwata S; Niimi F; Honda S; Okada H; Azuma T
Case Rep Urol; 2021; 2021():9936330. PubMed ID: 34306793
[TBL] [Abstract][Full Text] [Related]
5. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
[TBL] [Abstract][Full Text] [Related]
7. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
[TBL] [Abstract][Full Text] [Related]
8. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
9. Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
Meerveld-Eggink A; Graafland N; Wilgenhof S; Van Thienen JV; Lalezari F; Grant M; Szabados B; Abu-Ghanem Y; Kuusk T; Boleti E; Blank CU; Haanen JBAG; Powles T; Bex A
Eur Urol Open Sci; 2022 Jan; 35():54-58. PubMed ID: 35024632
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
11. Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review.
Zhou W; Huang J; He Q; Luo Q; Zhang X; Tao X; Dong H; Tu X
Front Oncol; 2021; 11():764352. PubMed ID: 34820330
[TBL] [Abstract][Full Text] [Related]
12. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
[TBL] [Abstract][Full Text] [Related]
13. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
Front Immunol; 2022; 13():980456. PubMed ID: 36238308
[TBL] [Abstract][Full Text] [Related]
14. [Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
Okuno Y; Tanaka R; Mikami K; Takeuchi T
Hinyokika Kiyo; 2020 Jan; 66(1):13-17. PubMed ID: 32028750
[TBL] [Abstract][Full Text] [Related]
15. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Sazuka T; Fujimoto A; Sato H; Arai T; Imamura Y; Sakamoto S; Ikeda JI; Ichikawa T
IJU Case Rep; 2021 Nov; 4(6):355-358. PubMed ID: 34755054
[TBL] [Abstract][Full Text] [Related]
16. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.
Okada T; Hamamoto S; Etani T; Naiki T; Sue Y; Banno R; Yamada K; Sakakura T; Yasui T
Int Cancer Conf J; 2020 Apr; 9(2):88-91. PubMed ID: 32257760
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
18. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab.
Fuchizawa H; Kijima T; Takada-Owada A; Nagashima Y; Okazaki A; Yokoyama M; Nishihara D; Ishida K; Kamai T
IJU Case Rep; 2021 Sep; 4(5):333-337. PubMed ID: 34497997
[TBL] [Abstract][Full Text] [Related]
19. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
Oya M; Tajima Y; Kabu K
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
[TBL] [Abstract][Full Text] [Related]
20. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
